163 related articles for article (PubMed ID: 38637844)
1. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
[TBL] [Abstract][Full Text] [Related]
2. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Lee IH; Chen GY; Chien CR; Cheng JC; Chen JL; Yang WC; Chen JS; Hsu FM
J Formos Med Assoc; 2021 Dec; 120(12):2176-2185. PubMed ID: 33451864
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
7. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
8. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
9. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
12. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Dosani M; Yang R; McLay M; Wilson D; Liu M; Yong-Hing CJ; Hamm J; Lund CR; Olson R; Schellenberg D
Curr Oncol; 2019 Feb; 26(1):e57-e63. PubMed ID: 30853810
[TBL] [Abstract][Full Text] [Related]
13. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
[TBL] [Abstract][Full Text] [Related]
14. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
[TBL] [Abstract][Full Text] [Related]
15. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
Scotti V; Bruni A; Francolini G; Perna M; Vasilyeva P; Loi M; Simontacchi G; Viggiano D; Lanfranchi B; Gonfiotti A; Topulli J; Olmetto E; Maragna V; Ferrari K; Bonti V; Comin C; Balduzzi S; D'Amico R; Lohr F; Voltolini L; Livi L
Clin Lung Cancer; 2019 Jan; 20(1):e53-e61. PubMed ID: 30348595
[TBL] [Abstract][Full Text] [Related]
20. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
de Ruiter JC; van Diessen JNA; Smit EF; van der Noort V; Damhuis RAM; Hartemink KJ;
Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35348664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
